Abstract
Current development of molecular targeted therapies in oncology is particularly active. This paper is a review of the recent advances in the field of molecular targeted therapies for head and neck squamous cell carcinoma (HNSCC). We analyze not only the recently published and ongoing clinical trials, but also the relevant preclinical studies, in order to identify the future directions of research in the field of HNSCC.
As epidermal growth factor receptor (EGFR) signaling pathway plays a key role in the growth of HNSCC, EGFR, with its downstream effectors, represents the main target of the new therapeutic agents currently in development. Today, cetuximab, an anti-EGFR monoclonal antibody, is the only targeted therapy approved for the treatment of HNSCC in patients with locally advanced tumors, in association with radiotherapy, and in patients with recurrent or metastatic disease, in association with platinum-based chemotherapy. Future advances are expected with the integration of cetuximab and other anti-EGFR agents into induction chemotherapeutic regimens or in association with concurrent chemoradiotherapy for locally advanced tumors. Besides EGFR inhibition, new molecular targeted therapies such as mTOR, Src kinase, or IGF-1R inhibitors, acting on other activated molecular signaling pathways, are being developed. As these innovative molecules are beginning to be used in clinical practice, the identification of predictive markers for efficacy and toxicity is now a crucial issue.Keywords: Cetuximab, EGFR, Head and neck squamous cell carcinoma, Molecular targeted therapies, Angiogenesis, oropharyngeal tumors, carboplatin, taxane, cisplatin arm.
Anti-Cancer Agents in Medicinal Chemistry
Title:Molecular Targeted Therapies in the Management of Head and Neck Squamous Cell Carcinoma: Recent Developments and Perspectives
Volume: 13 Issue: 3
Author(s): Alexandre Bozec, Frederic Peyrade and Gerard Milano
Affiliation:
Keywords: Cetuximab, EGFR, Head and neck squamous cell carcinoma, Molecular targeted therapies, Angiogenesis, oropharyngeal tumors, carboplatin, taxane, cisplatin arm.
Abstract: Current development of molecular targeted therapies in oncology is particularly active. This paper is a review of the recent advances in the field of molecular targeted therapies for head and neck squamous cell carcinoma (HNSCC). We analyze not only the recently published and ongoing clinical trials, but also the relevant preclinical studies, in order to identify the future directions of research in the field of HNSCC.
As epidermal growth factor receptor (EGFR) signaling pathway plays a key role in the growth of HNSCC, EGFR, with its downstream effectors, represents the main target of the new therapeutic agents currently in development. Today, cetuximab, an anti-EGFR monoclonal antibody, is the only targeted therapy approved for the treatment of HNSCC in patients with locally advanced tumors, in association with radiotherapy, and in patients with recurrent or metastatic disease, in association with platinum-based chemotherapy. Future advances are expected with the integration of cetuximab and other anti-EGFR agents into induction chemotherapeutic regimens or in association with concurrent chemoradiotherapy for locally advanced tumors. Besides EGFR inhibition, new molecular targeted therapies such as mTOR, Src kinase, or IGF-1R inhibitors, acting on other activated molecular signaling pathways, are being developed. As these innovative molecules are beginning to be used in clinical practice, the identification of predictive markers for efficacy and toxicity is now a crucial issue.Export Options
About this article
Cite this article as:
Bozec Alexandre, Peyrade Frederic and Milano Gerard, Molecular Targeted Therapies in the Management of Head and Neck Squamous Cell Carcinoma: Recent Developments and Perspectives, Anti-Cancer Agents in Medicinal Chemistry 2013; 13 (3) . https://dx.doi.org/10.2174/187152013804910370
DOI https://dx.doi.org/10.2174/187152013804910370 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Dual EGFR and COX-2 Inhibition as a Novel Approach to Targeting Head and Neck Squamous Cell Carcinoma
Current Cancer Drug Targets Gold Nanoparticles: Promising Agent to Improve the Diagnosis and Therapy of Cancer
Current Drug Metabolism Farnesyltransferase Inhibitors: A Detailed Chemical View on an Elusive Biological Problem
Current Medicinal Chemistry Endoglin (CD105): A Target for Anti-angiogenetic Cancer Therapy
Current Drug Targets Inhibition of Autophagy Strengthens Celastrol-Induced Apoptosis in Human Pancreatic Cancer In Vitro and In Vivo Models
Current Molecular Medicine Peptides in Oral Diseases
Current Pharmaceutical Design Natural Compounds as Antagonists of Canonical Wnt/β-Catenin Signaling
Current Chemical Biology Recent Advances in Curcumin Treated Non-Small Cell Lung Cancers: An Impetus of Pleiotropic Traits and Nanocarrier Aided Delivery
Current Medicinal Chemistry Applied Proteomics in Companion Animal Medicine
Current Proteomics Modulating Mesenchymal Stromal Cell Function with Cholesterol Synthesis Inhibitors
Current Medicinal Chemistry Strategies that Target Tight Junctions for Enhanced Drug Delivery
Current Pharmaceutical Design Thymidine Phosphorylase Over-Expression in Oral Squamous Carcinoma Tissue as a Potential Target of Capecitabine
Letters in Drug Design & Discovery Assessment of the Mitotic Spindle Assembly Checkpoint (SAC) as the Target of Anticancer Therapies
Current Cancer Drug Targets Targeting Angiogenesis for Treatment of NSCLC Brain Metastases
Current Cancer Drug Targets Role of Erlotinib in Influencing the Quality of Life of Cancer Patients
Clinical Cancer Drugs The Toll-Like Receptor Radical Cycle Pathway: A New Drug Target in Immune-Related Chronic Fatigue
CNS & Neurological Disorders - Drug Targets Phytoestrogens and Prostate Cancer
Current Drug Targets ES-MDA: Enhanced Similarity-based MiRNA-Disease Association
Current Protein & Peptide Science Effective Inhibition of Mitochondrial Metabolism by Cryptotanshinone in MDA-MB231 cells: A Proteomic Analysis
Current Proteomics Sentinel Lymph Node Identification in Patients with Stage IB1 Invasive Cervical Carcinoma
Current Cancer Therapy Reviews